Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol and Midodrine vs Carvedilol Alone for Early Rebleed in Cirrhosis
NCT07465471Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of midodrine in Variceal bleeding (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients with early variceal rebleed at 6 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
midodrine
03
Conditions
Variceal bleeding
Beyond the preview
Go deeper on NCT07465471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465471.